Pan-Cancer Comprehensive Genomic Profiling of Solid Tumors
Gain an expansive view of your solid tumor samples by targeting 523 cancer-related genes using the TruSight Oncology 500 comprehensive assay. Not only does this assay identify all relevant variants (SNVs, insertions, deletions, CNVs, gene fusions, and transcript variants) across various tumor types, but it also reports tumor mutational burden (TMB) score and microsatellite instability (MSI) status.
Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.